Skip to content

Anesthetic Management in Patients Undergoing Epicardial Ablation

Anesthetic Management in Patients Undergoing Epicardial Ablation for the Treatment of Ventricular Tachycardia; Retrospective Study

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06538987
Enrollment
22
Registered
2024-08-06
Start date
2024-08-30
Completion date
2024-10-30
Last updated
2025-05-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ventricular Tachycardia

Keywords

anesthesia, ventricular tachycardia, Electrophysiology, electro-anatomic mapping, catheter ablation, risk assessment

Brief summary

The study is a retrospective study and is descriptive in nature. In this study, the investigators aimed to emphasize the importance of anesthesia management by cardiac risk assessment of patients undergoing epicardial ablation under general anesthesia and analysis of complications that developed during the procedure.

Detailed description

The study is retrospective observational and data were collected by examining the files of all epicardial ablation patients received in the angiography unit starting from 30.10.2020 until 30.10.2022 after ethics committee approval is obtained. Baseline characteristic features of the patients Sex, Age, (years, BMI (kg/m2) Hypertension, Coronary artery disease, COPD (Chronic obstructive pulmonary disease), CKD (Chronic kidney disease) Electrical storm, and ventricular tachycardia etiology, Ischemic cardiomyopathy, Dilated cardiomyopathy, the presence of ARVC (Arrhythmogenic Right Ventricular Cardiomyopathy), Hypertrophic cardiomyopathy will be recorded. NHYA classification will be examined in two groups as NHYA I or II and NHYA III or IV, also estimated glomerular filtration rate, left ventricular ejection fraction, PAAINESD (acute hemodynamic decompensation risk assessment score), iVT score (Risk of VT recurrence) Score information will be recorded. Ventricular tachycardia focus locations, dopamine, dobutamine, norepinephrine infusion requirement during the procedure, arrest development during the procedure, fluoroscopy time and ablation times will be recorded. In the follow-up of the patients after the procedure Causes of death, decompensated heart failure, transient ischemic attack, development of acute renal failure, and recurrence of ventricular tachycardia will be recorded. PAAINESD score (acute hemodynamic decompensation risk assessment score) will be recorded. The PAAINESD Score, developed to estimate the risk of periprocedural hemodynamic decompensation, has values ranging from 0 to 35 points (or 0 to 31 \[PAINESD\] when the modifiable intraprocedural variable general anesthesia is excluded). duration of the procedure, the need for inotropes during the procedure, whether the patient needed mechanical ventilation after the procedure, and the success rates after the procedure will be recorded. PAINESD Pulmonary disease (chronic obstructive pulmonary disease) 5 Age \>60 years 3 Anaesthesia (general) 4 Ischaemic cardiomyopathy 6 NYHA class III or IV 6 Ejection fraction \<25 % 3 Storm (VT). 5 Diabetes 3 Data will be analyzed in three separate categories, the characteristics of the patients before the procedure, during the procedure and after the procedure. Descriptive tables and percentages of parameters will be created by statistical analysis.

Interventions

PROCEDUREpercutaneous epicardial ablation

Epicardial catheter ablation is often necessary for the successful treatment of scar-induced ventricular tachycardia (VT), especially in patients with nonischemic cardiomyopathy (NICMP) where scarring is more extensive on the mid-myocardial or epicardial surface. Because epicardial mapping can be painful and patient movement can limit mapping and safe epicardial access, a common strategy for these patients is general anesthesia.

Sponsors

Eskisehir Osmangazi University
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

• age \> 18 years old who underwent elective VT ablation between 2020 - 2022, * primary anesthetic type listed as general anesthesia

Exclusion criteria

• age \< 18 years, * missing follow-up data, * patients who have previously undergone epicardial ablation

Design outcomes

Primary

MeasureTime frameDescription
Ablation time2 yearsminutes
glomerular filtration rate (eGFR)2 yearsml/dak/1,73m2
Total procedural time2 yearsminutes
Fluoroscopy time2 yearsminutes
sex2 yearsmale %
age2 yearsyears
weight2 yearskilograms
height2 yearsmeters
Hypertension2 yearsyes or no
Diabetes mellitus2 yearsyes or no
Coronary artery disease2 yearsyes or no
Chronic obstructive pulmonary disease2 yearsyes or no
Chronic kidney disease2 yearsyes or no
Systolic pulmonary artery pressure2 yearsmmHg
Left ventricular ejection2 years%
PAAINESD (Acute hemodynamic decompensation risk assessment, ranging from 0 to 35 points, 35 point is the worst) score2 yearsscore 0-35
ASA ( American Society of Anesthesiologists (ASA) physical status classification ranging from I to IV2 yearsscore I-IV
Hemoglobin2 yearsg/dl

Secondary

MeasureTime frameDescription
Exitus during the follow-up2 yearsyes or no
cause of death2 yearsEnd-Stage heart failure, VT storm
Transient ischemic attack after procedure2 yearsyes or no

Countries

Turkey (Türkiye)

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026